Early allopurinol initiation in acute gout flare has no significant benefit: Study
Gout is among the most prevalent etiologies of chronic inflammatory arthritis in the United States. The evaluation and management of gout and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.
A new study by Panchalee Satpanic reported that early allopurinol initiation during an acute gout flare did not show significant changes in time to resolution, flare recurrence, and inflammatory markers. This study is published in Clinical Rheumatology.
The objective of the study was to compare the time to complete resolution of acute gout flare between early and late allopurinol initiation.
The study was 28-day, randomized controlled, open-label trial included patients with crystal-proven gout who were presented with acute gout flare within 72 h of arthritis onset. Exclusion criteria were advanced renal failure, ongoing ULT, and presence of the HLA-B*5801 allele. Allopurinol was used on days 1 and 14 in early and late groups, respectively. Primary outcome was time to complete arthritis resolution, and secondary outcomes were time to clinical resolution; arthritis relapse; laboratory parameters; and adverse events.
The results of the study were found to be
• A total of 117 patients were randomized to early and late allopurinol groups (n = 59 and 58, respectively).
• One patient in each group was lost to follow-up; therefore, 115 patients were included in the modified intention-to-treat analysis.
• Baseline characteristics were comparable between the groups. The median time to complete resolution was not significantly different between the early and late allopurinol groups (6 [5–14] and 6 [5–7] days, respectively; p = 0.14).
• The median time to clinical resolution was 4 [3–6] days in both groups (p = 0.12). Other secondary outcomes were not significantly different. Serious adverse events did not occur in either group.
Satpanic and team concluded that "Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers."
For further information: Satpanich P, Pongsittisak W, Manavathongchai S. Early versus late allopurinol initiation in acute gout flare (ELAG): a randomized controlled trial. Clin Rheumatol. Published online August 18, 2021. doi:10.1007/s10067-021-05872-8
